Mills Sarah C, von Roon Alexander C, Tekkis Paris P, Orchard Timothy R
Lister Hospital, Stevenage, UK.
BMJ Clin Evid. 2011 Apr 27;2011:0416.
Crohn's disease is a chronic condition of the gastrointestinal tract. It is characterised by transmural, granulomatous inflammation that occurs in a discontinuous pattern, with a tendency to form fistulae. The cause is unknown but may depend on interactions between genetic predisposition, environmental triggers, and mucosal immunity.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of medical treatments to induce remission in adults with Crohn's disease? What are the effects of surgical interventions to induce and maintain remission in adults with small-bowel Crohn's disease? What are the effects of surgical interventions to induce remission in adults with colonic Crohn's disease? What are the effects of medical interventions to maintain remission in adults with Crohn's disease; and to maintain remission following surgery? What are the effects of lifestyle interventions to maintain remission in adults with Crohn's disease? We searched: Medline, Embase, The Cochrane Library, and other important databases up to December 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 93 systematic reviews, RCTs, or observational studies that met our inclusion criteria.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: aminosalicylates, antibiotics, azathioprine/mercaptopurine, ciclosporin, corticosteroids (oral), enteral nutrition, fish oil, infliximab, methotrexate, probiotics, resection, segmental colectomy, smoking cessation, and strictureplasty.
克罗恩病是一种胃肠道的慢性疾病。其特征为透壁性、肉芽肿性炎症,呈节段性分布,并有形成瘘管的倾向。病因不明,但可能取决于遗传易感性、环境触发因素和黏膜免疫之间的相互作用。
我们进行了一项系统评价,旨在回答以下临床问题:药物治疗对诱导成年克罗恩病患者缓解的效果如何?手术干预对诱导和维持成年小肠克罗恩病患者缓解的效果如何?手术干预对诱导成年结肠克罗恩病患者缓解的效果如何?药物干预对维持成年克罗恩病患者缓解以及术后维持缓解的效果如何?生活方式干预对维持成年克罗恩病患者缓解的效果如何?我们检索了:截至2009年12月的医学期刊数据库(Medline)、荷兰医学文摘数据库(Embase)、考克兰图书馆以及其他重要数据库(临床证据综述会定期更新,请查看我们的网站获取本综述的最新版本)。我们纳入了来自美国食品药品监督管理局(FDA)和英国药品与保健品管理局(MHRA)等相关组织的危害警示。
我们找到了93项符合我们纳入标准的系统评价、随机对照试验或观察性研究。
在本系统评价中,我们呈现了以下干预措施的有效性和安全性相关信息:氨基水杨酸类药物、抗生素、硫唑嘌呤/巯嘌呤、环孢素、口服糖皮质激素、肠内营养、鱼油、英夫利昔单抗、甲氨蝶呤、益生菌、切除术、节段性结肠切除术、戒烟以及狭窄成形术。